Relevance of Helicobacter pylori virulence factors for vaccine development

Helicobacter pylori infection increases the risk for a wide spectrum of clinical outcomes, ranging from peptic ulcer disease to gastric cancer. However, the infection induces gastric and duodenal ulceration or gastric cancer in only a minority of infected subjects because H. pylori strains are genet...

Descripción completa

Detalles Bibliográficos
Autores: Luz del Carmen Hernández-Hernández, Eduardo César Lazcano-Ponce, Yolanda López-Vidal, Germán Rubén Aguilar-Gutiérrez
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:México
Institución:Universidad Nacional Autónoma de México
Repositorio:Redalyc-UNAM
OAI Identifier:oai:redalyc.org:10612557010
Acceso en línea:https://www.redalyc.org/articulo.oa?id=10612557010
Access Level:acceso abierto
Palabra clave:Salud
vaccines
gastric cancer
virulence factors
Helicobacter pylori
id MX_7ebb5fbea8f84eea2e99da94a46cabe4
oai_identifier_str oai:redalyc.org:10612557010
network_acronym_str MX
network_name_str México
repository_id_str
spelling Relevance of Helicobacter pylori virulence factors for vaccine developmentLuz del Carmen Hernández-HernándezEduardo César Lazcano-PonceYolanda López-VidalGermán Rubén Aguilar-GutiérrezSaludvaccinesgastric cancervirulence factorsHelicobacter pyloriHelicobacter pylori infection increases the risk for a wide spectrum of clinical outcomes, ranging from peptic ulcer disease to gastric cancer. However, the infection induces gastric and duodenal ulceration or gastric cancer in only a minority of infected subjects because H. pylori strains are genetically diverse and express different virulence factors. Individuals infected with strains that express these virulence factors probably develop severe diseases such as gastric cancer. Nevertheless, the ancient relationship between H. pylori and humans suggests that some strains could be beneficial to human health, which means that generalized administration of antibiotic therapy could eventually cause problems. The development of vaccines based on virulence factors that provide long-term protection is the best strategy for control and/or elimination of pathogenic strains. The different immunization schemes and formulations designed to evaluate the vaccines based on virulence factors in animal models have offered promising results. However, it is necessary to determine whether or not these results can be reproduced in humans. This article reviews recent vaccination studies that explore this possibility: oral vaccines using urease or inactivated whole cells plus LT as adjuvant and urease expressed in Salmonella spp. vectors, as well as a parenteral multicomponent vaccine plus aluminum hydroxide as adjuvant. Although these studies have achieved limited success, they have established support for the development of an effective vaccine against this infection.Instituto Nacional de Salud Pública2009info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdf0036-3634https://www.redalyc.org/articulo.oa?id=10612557010Salud Pública de México (México) Num.3 Vol.51reponame:Redalyc-UNAMinstname:Universidad Nacional Autónoma de Méxicoinstacron:UNAMenhttp://www.redalyc.org/revista.oa?id=106Salud Pública de Méxicoinfo:eu-repo/semantics/openAccessoai:redalyc.org:106125570102025-09-03T18:02:05Z
dc.title.none.fl_str_mv Relevance of Helicobacter pylori virulence factors for vaccine development
title Relevance of Helicobacter pylori virulence factors for vaccine development
spellingShingle Relevance of Helicobacter pylori virulence factors for vaccine development
Luz del Carmen Hernández-Hernández
Salud
vaccines
gastric cancer
virulence factors
Helicobacter pylori
title_short Relevance of Helicobacter pylori virulence factors for vaccine development
title_full Relevance of Helicobacter pylori virulence factors for vaccine development
title_fullStr Relevance of Helicobacter pylori virulence factors for vaccine development
title_full_unstemmed Relevance of Helicobacter pylori virulence factors for vaccine development
title_sort Relevance of Helicobacter pylori virulence factors for vaccine development
dc.creator.none.fl_str_mv Luz del Carmen Hernández-Hernández
Eduardo César Lazcano-Ponce
Yolanda López-Vidal
Germán Rubén Aguilar-Gutiérrez
author Luz del Carmen Hernández-Hernández
author_facet Luz del Carmen Hernández-Hernández
Eduardo César Lazcano-Ponce
Yolanda López-Vidal
Germán Rubén Aguilar-Gutiérrez
author_role author
author2 Eduardo César Lazcano-Ponce
Yolanda López-Vidal
Germán Rubén Aguilar-Gutiérrez
author2_role author
author
author
dc.subject.none.fl_str_mv Salud
vaccines
gastric cancer
virulence factors
Helicobacter pylori
topic Salud
vaccines
gastric cancer
virulence factors
Helicobacter pylori
description Helicobacter pylori infection increases the risk for a wide spectrum of clinical outcomes, ranging from peptic ulcer disease to gastric cancer. However, the infection induces gastric and duodenal ulceration or gastric cancer in only a minority of infected subjects because H. pylori strains are genetically diverse and express different virulence factors. Individuals infected with strains that express these virulence factors probably develop severe diseases such as gastric cancer. Nevertheless, the ancient relationship between H. pylori and humans suggests that some strains could be beneficial to human health, which means that generalized administration of antibiotic therapy could eventually cause problems. The development of vaccines based on virulence factors that provide long-term protection is the best strategy for control and/or elimination of pathogenic strains. The different immunization schemes and formulations designed to evaluate the vaccines based on virulence factors in animal models have offered promising results. However, it is necessary to determine whether or not these results can be reproduced in humans. This article reviews recent vaccination studies that explore this possibility: oral vaccines using urease or inactivated whole cells plus LT as adjuvant and urease expressed in Salmonella spp. vectors, as well as a parenteral multicomponent vaccine plus aluminum hydroxide as adjuvant. Although these studies have achieved limited success, they have established support for the development of an effective vaccine against this infection.
publishDate 2009
dc.date.none.fl_str_mv 2009
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 0036-3634
https://www.redalyc.org/articulo.oa?id=10612557010
identifier_str_mv 0036-3634
url https://www.redalyc.org/articulo.oa?id=10612557010
dc.language.none.fl_str_mv en
language_invalid_str_mv en
dc.relation.none.fl_str_mv http://www.redalyc.org/revista.oa?id=106
dc.rights.none.fl_str_mv Salud Pública de México
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Salud Pública de México
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Salud Pública
publisher.none.fl_str_mv Instituto Nacional de Salud Pública
dc.source.none.fl_str_mv Salud Pública de México (México) Num.3 Vol.51
reponame:Redalyc-UNAM
instname:Universidad Nacional Autónoma de México
instacron:UNAM
instname_str Universidad Nacional Autónoma de México
instacron_str UNAM
institution UNAM
reponame_str Redalyc-UNAM
collection Redalyc-UNAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1858175870365073408
score 14.964248

Similares en LA Referencia